| Literature DB >> 31521179 |
Rubén Hernández de Paz1, Diego Serrano-Muñoz2, Soraya Pérez-Nombela1, Elisabeth Bravo-Esteban1, Juan Avendaño-Coy1, Julio Gómez-Soriano1.
Abstract
BACKGROUND: Transcranial direct-current stimulation (tDCS) is an easy-to-apply, cheap, and safe technique capable of affecting cortical brain activity. However, its effectiveness has not been proven for many clinical applications.Entities:
Keywords: Gait; Neurological disorder; Rehabilitation; Transcranial direct-current stimulation
Mesh:
Year: 2019 PMID: 31521179 PMCID: PMC6744683 DOI: 10.1186/s12984-019-0591-z
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Methodological quality of included articles in accordance with the PEDro scale
| Geroin et al., 2011 [ | Manji et al., 2018 [ | Yotnuengnit et al., 2017 [ | Chang, Kim, & Park., 2015 [ | Raithatha et al., 2016 [ | Seo et al., 2017 [ | Costa-Ribeiro et al., 2017 [ | Kumru et al., 2016 [ | |
|---|---|---|---|---|---|---|---|---|
| Eligibility criteria | √ | √ | √ | √ | √ | √ | √ | |
| Random allocation | √ | √ | √ | √ | √ | √ | √ | √ |
| Concealed allocation | √ | √ | √ | |||||
| Basal intergroup similarities | √ | √ | √ | √ | √ | √ | ||
| Blinding of participants | √ | √ | √ | √ | √ | √ | √ | √ |
| Blinding of therapists | √ | √ | ||||||
| Blinding of assessors | √ | √ | √ | √ | √ | √ | √ | √ |
| Follow-up | √ | √ | √ | √ | √ | √ | √ | |
| Intention-to-treat analysis | √ | √ | √ | √ | √ | |||
| Intergroup statistical comparison | √ | √ | √ | √ | √ | √ | √ | √ |
| Point measures and variability measures | √ | √ | √ | √ | √ | √ | √ | √ |
| Total score | 7/10 | 9/10 | 8/10 | 8/10 | 7/10 | 8/10 | 8/10 | 8/10 |
Fig. 1Flow of articles during the selection process
Main characteristics and outcomes of the reviewed articles
| Article | Pathology; N for the intervention group | Area of application and tDCS parameters (current density; duration) | Number of sessions; intervals | Design | Order of application; control group | Variables | Gait rehabilitation treatment; duration | Effect versus placebo (% difference, |
|---|---|---|---|---|---|---|---|---|
| Geroin et al., 2011 [ | Stroke; | A = PMI- affected LL, C = SO to-CL; DC: 0,04 mA/cm2; 7 min. | 10 s; 2 weeks. | EV.1 = Pre EV.2 = Post EV.3 = 2 weeks post | ONLINE; Off since the beginning. | 6MWT, 10MWT, BPG, FAC, RMI, MILS, MAS. | Exoskeleton robot; 20 min. | SNS |
| Manji et al., 2018 [ | Stroke; (crossover design) | A = 3.5 cm anterior to Cz (SMA), C = EOC; DC: 0.04 mA/cm2; 20 min. | 7 s; 1 week (3-day washout period) | EV.1 = Pre EV.2 = Post | ONLINE; UNK. | 10MWT, TUG, FMA, POMA, TIS. | Exoskeleton-robot; 20 min. | ↓10MWT (9.09%, |
| Yotnuengnit et al., 2017 [ | PD; | A = Cz (PMA-LL), C = SOA; DC: 0.06 mA/cm2; 30 min. | 6 s; 2 weeks. | EV.1 = Pre EV.2 = Post EV.3 = 2 weeks post EV.4 = 6 weeks post | OFFLINE; Gradually off after 1 min. | BPG, UPDRS. | Conventional physiotherapy; 30 min. | SNS |
| Chang, Kim, & Park., 2015 [ | Stroke; | A = APC of TA (PMA-affected LL), C = SOA-CL; A = 0.28 mA/cm2, C = 0.07 mA/cm2; 10 min. | 10 s; 2 weeks. | EV.1 = pre EV.2 = 1 day post | ONLINE; Off after 15 s. | MEP of TA, BPG, FMA, MILS, FAC, BBS | Conventional physiotherapy; 30 min. | MEPs: ↓Latency (8.61%, ↑FMA (6.27%, |
| Raithatha et al., 2016 [ | SCI; | A = PMA-LL, C = SOA; A = 0.08 mA/cm2, C = 0.06 mA/cm2; 20 min. | 36 s; 12 weeks. | EV.1 = pre EV.2 = post EV.3 = 4 weeks post | OFFLINE; Off after 30 s. | MMT, 6MWT, 10MWT, TUG, BBS, SCIM-III. | Exoskeleton robot; 1 h. | ↑ MMT right at EV.2 (70.54%, ↑TUG in control group ↑6MWT in control group |
| Seo et al., 2017 [ | Stroke; N = 9 | A = lateral to CZ (PMI- affected LL), C = SOA-CL; DC: 0.06 mA/cm2; 20 min. | 10 s; 2 weeks. | EV.1 = pre EV.2 = post EV.3 = 4 weeks post | OFFLINE; Off after 1 min. | FAC, 10MWT, 6MWT, BBS, FMA, MRCS, MEP (not in EV3). | Exoskeleton robot; 45 min. | ↑FAC (44.5%, |
| Costa-Ribeiro et al., 2017 [ | PD; | A = 2 cm anterior to CZ (PMA-LL), C = SOA-CL; CD: 0.06 mA/cm2; 13 min. | 10 s; 4 weeks. | EV.1 = pre EV.2 = post EV.3 = 4 weeks post | OFFLINE; Off after 30 s. | 10MWT, TUG, BPG, UPDRS part III (for motor deterioration), and UPDRS-Brad (bradykinesia), PDQ-39, BBS. | Visual cueing; 30 min. | SNS |
| Kumru et al., 2016 [ | SCI; | A = PMA-LL (vertex), C = SOA non-dominant; CD: 0.06 mA/cm2; 20 min. | 20 s; 4 weeks. | EV.1 = pre EV.2 = post EV.3 = 4 weeks post | ONLINE; Off after 30 s. | LEMS (not at EV3), 10MWT, WISCI. | Exoskeleton robot; 30 min. | SNS |
10MWT 10-m walk test, 6MWT 6-min walking test, A anode, APC affected pre-central convolution, BBS Berg Balance scale, BPG biomechanical parameters of gait, C cathode, CD Current density, PD Parkinson’s disease, CL contra-lateral, CZ Cz area in accordance with the “International 10–20 System (EEC)”, EOC exterior occipital crest, EV evaluation, FAC functional ambulation categories, FMA Fugl-Meyer assessment, LEMS lower extremity motor score, LL lower limb, MAS modified Ashworth scale, MEP motor-evoked potential, MILS Motricity Index leg subscore, MMT manual muscle testing, MRCS Medical Research Council scale, OFFLINE tDCS applied before the intervention, PDQ-39 Parkinson’s Disease Questionnaire-39, PMA primary motor area, POMA performance-oriented mobility assessment, RMI rivermead mobility index, SCI spinal cord injury, SCIM-III Spinal Cord Injury Measure, SMA supplementary motor area, SNS Statistically non-significant, SOA supra-orbital area, TA tibial anterior, TIS trunk impairment scale, TUG Timed Up and Go test, UL-MT upper limb motor task, UNK unknown, UPDRS unified Parkinson’s disease rating scale, WISCI walking index for spinal cord independence